Initial experience with Gallium-68 and Lutetium-177 prostate-specific membrane antigen theranostics for prostate cancer in the Philippines: A case series
- Author:
Miguel Antonio C. Catangui
1
;
Patricia A Bautista
1
;
Emily Mia C. Acayan
1
;
Raquel Marie R. Cabatu-Key
1
Author Information
1. Department of Nuclear Medicine and PET Center, St. Lukes Medical Center, Quezon City, Philippines
- Publication Type:Other Types
- Keywords:
Ga-68 PSMA
- MeSH:
Positron Emission Tomography Computed Tomography;
Precision Medicine;
Prostatic Neoplasms;
Philippines
- From:
The Philippine Journal of Nuclear Medicine
2019;14(1):11-15
- CountryPhilippines
- Language:English
-
Abstract:
In the Philippines, prostate cancer is the third most common malignancy among men. Over time, it tends to recur and/or progress to metastatic castration-resistant prostate cancer, wherein conventional therapies no longer work. Taking advantage of the high expression of prostate-specific membrane antigen (PSMA) on prostate cancer cells, 68GA- and 177 Lu-PSMA theranostics provides a targeted approach to imaging and therapy. With it's availabity in our country, patients now have an appealing and accessible treatment option. In this paper, we present five cases of metastatic castration-resistant prostate cancer, who have undergone 68Ga-PSMA PET/CT scans and 177Lu-PSMA radioligand therapies in the Philippines, to showcase the usefulness of theranostics in the local setting.
- Full text:Initial Experience.pdf
